Bender Robert & Associates Purchases in Q2 2025

Bender Robert & Associates

  • $448 Million
  • Q2 2025
Stock Shares change Price Range Shares Held Trade History
URGN
Uro Gen Pharma Ltd.

Healthcare
34.7K
New
$3.9 - $15.46 $135K - $536K
34.7K $475K
RSP
Invesco S&P 500 Equal Weight E

ETFs
1.27K
New
$152.93 - $181.74 $195K - $232K
1.27K $231K
EOLS
Evolus, Inc.

Healthcare
25.1K
New
$9.1 - $12.22 $228K - $306K
25.1K $230K
AVGO
Broadcom Inc.

Technology
775
New
$146.29 - $275.65 $113K - $214K
775 $213K
BCRX
Biocryst Pharmaceuticals Inc

Healthcare
23.7K
New
$6.41 - $11.19 $152K - $265K
23.7K $212K
PLSE
Pulse Biosciences, Inc.

Healthcare
11.6K
New
$14.48 - $19.27 $168K - $223K
11.6K $174K
V
Visa Inc.

Financial Services
42
+ 4.16%
$308.27 - $373.31 $12.9K - $15.7K
1.05K $373K
ABT
Abbott Laboratories

Healthcare
30
+ 0.73%
$123.95 - $138.08 $3.72K - $4.14K
4.12K $559K
Activity Summary
Buys All Purchases 8 New Holdings 6 Increased Positions 2 Sells All Sells 33 Reductions 33 Sold out 0 Options Calls 0 Puts 0
Track This Portfolio

Track Bender Robert & Associates Portfolio

Follow Bender Robert & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bender Robert & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Bender Robert & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email